Sanofi-Aventis & MMV to Develop Malaria Treatments

The research project aims to develop drug candidates from a set of Sanofi-Aventis’ compounds selected for their potential activity against malaria parasites.

French drugmaker Sanofi-Aventis has inked a three-year research agreement with Medicines for Malaria Venture (MMV) to develop malaria treatments. The two companies will jointly identify new candidate compounds to treat malaria and conduct early development programmes to demonstrate proof of concept in man.

The research project, called Orthology Malaria, aims to develop drug candidates from a set of Sanofi-Aventis’ compounds selected for their potential activity against malaria parasites. Each stage of the project will be evaluated by a Sanofi-Aventis/MMV joint steering committee and assessed according to MMV’s criteria for compound progression.

Elias Zerhouni, president, Global Research